Bolt Biotherapeutics, Inc.
BOLT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001641281
In the last 90 days, Bolt Biotherapeutics, Inc. insiders filed 2 open-market purchases and 3 sales; 23 institutions reported holding it in 13F filings for Q2 2026, worth $2.31M in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in Bolt Biotherapeutics, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 37
- −2 vs. Q1 2024
- Shares held
- 22.6M
- −1.38M (−5.7%) vs. Q1 2024
- Total value
- $17.0M
- −$16.6M (−49.5%) vs. Q1 2024
- New holders
- 4
- 13 more added
- Sold out
- 6
- 6 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BOLT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 23 | $2.31M |
| Q1 2026 | 24 | $2.49M |
| Q4 2025 | 21 | $3.30M |
| Q3 2025 | 24 | $4.28M |
| Q2 2025 | 25 | $5.10M |
| Q1 2025 | 30 | $7.33M |
| Q4 2024 | 38 | $9.99M |
| Q3 2024 | 32 | $12.2M |
| Q2 2024 | 37 | $17.0M |
| Q1 2024 | 39 | $33.6M |
| Q4 2023 | 40 | $27.0M |
| Q3 2023 | 35 | $25.5M |
| Q2 2023 | 40 | $32.1M |
| Q1 2023 | 41 | $32.4M |
| Q4 2022 | 44 | $26.8M |
| Q3 2022 | 56 | $39.7M |
| Q2 2022 | 62 | $54.8M |
| Q1 2022 | 66 | $79.3M |
| Q4 2021 | 62 | $164.6M |
| Q3 2021 | 72 | $449.1M |
| Q2 2021 | 61 | $513.8M |
| Q1 2021 | 70 | $1.04B |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Bolt Biotherapeutics, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 358 | $0 | 0.00% | +357+35,700.0% | Added |
| Qube Research & Technologies Ltd | 2 | $2 | 0.00% | 00.0% | Unchanged |
| Salem Investment Counselors Inc | 40 | $30 | 0.00% | 00.0% | Unchanged |
| Barclays PLC | 139 | $104 | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 184 | $138 | 0.00% | −5,362−96.7% | Reduced |
| Bank of America Corp | 628 | $471 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 840 | $630 | 0.00% | 00.0% | Unchanged |
| Steward Partners Investment Advisory, LLC | 1,000 | $750 | 0.00% | +1,000 | New |
| Advisor Group Holdings, Inc. | 15,000 | $11.3K | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 22,410 | $16.8K | 0.00% | +22,410 | New |
| Morgan Stanley | 33,687 | $25.3K | 0.00% | +9,000+36.5% | Added |
| Assenagon Asset Management S.A. | 34,488 | $25.9K | 0.00% | +34,488 | New |
| Northern Trust Corp | 40,895 | $30.7K | 0.00% | −110−0.3% | Reduced |
| Jane Street Group, LLC | 41,528 | $31.1K | 0.00% | +41,528 | New |
| State Street Corp | 47,437 | $35.6K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 48,825 | $36.6K | 0.00% | +36,654+301.2% | Added |
| Two Sigma Securities, LLC | 53,886 | $40.4K | 0.00% | +30,072+126.3% | Added |
| Prudential Financial Inc | 54,400 | $40.8K | 0.00% | +19,200+54.5% | Added |
| Bridgeway Capital Management, LLC | 85,200 | $63.9K | 0.00% | −26,000−23.4% | Reduced |
| FMR LLC | 86,613 | $65.0K | 0.00% | +7,714+9.8% | Added |
| Marquette Asset Management, LLC | 113,797 | $85.3K | 0.01% | +17,124+17.7% | Added |
| ADAR1 Capital Management, LLC | 185,999 | $139.5K | 0.03% | +180,999+3,620.0% | Added |
| BlackRock Inc. | 267,068 | $200.3K | 0.00% | +12,110+4.7% | Added |
| Renaissance Technologies LLC | 276,739 | $207.6K | 0.00% | −240,898−46.5% | Reduced |
| Geode Capital Management, LLC | 370,790 | $278.1K | 0.00% | +23,223+6.7% | Added |
| Adage Capital Partners GP, L.L.C. | 500,000 | $375.0K | 0.00% | 00.0% | Unchanged |
| Acuitas Investments, LLC | 630,507 | $472.9K | 0.25% | +112,555+21.7% | Added |
| Board of Trustees of The Leland Stanford Junior University | 719,546 | $539.7K | 0.04% | 00.0% | Unchanged |
| Samsara BioCapital, LLC | 1,049,153 | $786.9K | 0.16% | 00.0% | Unchanged |
| Vanguard Group Inc | 1,067,405 | $800.6K | 0.00% | +29,802+2.9% | Added |
| Nan Fung Group Holdings Ltd | 1,166,952 | $875.2K | 0.93% | 00.0% | Unchanged |
| Newtyn Management, LLC | 1,363,234 | $1.02M | 0.19% | −336,766−19.8% | Reduced |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,891,467 | $1.42M | 1.09% | 00.0% | Unchanged |
| Citadel Advisors LLC | 2,367,511 | $1.78M | 0.00% | −48,217−2.0% | Reduced |
| Sofinnova Investments, Inc. | 2,754,437 | $2.07M | 0.13% | 00.0% | Unchanged |
| Vivo Capital, LLC | 3,521,291 | $2.64M | 0.24% | 00.0% | Unchanged |
| Tang Capital Management LLC | 3,812,773 | $2.86M | 0.29% | +392,773+11.5% | Added |
| OrbiMed Advisors LLC | 0 | $0 | 0.00% | −1,541,000−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −78,020−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −45,956−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −12,826−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −10,938−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −211−100.0% | Sold out |